Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.

Autor: Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Babak Myeloma Group, Faculty of Medicine, Masaryk University, Brno, Czech Republic. pour.ludek@fnbrno.cz., Szarejko M; University Clinical Centre, Department of Hematology and Transplantology, Gdansk., Bila J; Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade., Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo., Spicka I; 1^st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic., Maisnar V; 4^th Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic., Jurczyszyn A; Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Faculty of Medicine, Krakow., Grudeva-Popova Z; Department of Clinical Oncology, Medical Faculty, Medical University of Plovdiv, Plovdic, Bulgaria., Hájek R; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Usenko G; City Clinical Hospital No. 4 of Dnipro City Council, Dnipro, Ukraine., Thuresson M; Oncopeptides AB, Stockholm., Norin S; Oncopeptides AB, Stockholm., Jarefors S; Oncopeptides AB, Stockholm., Bakker NA; Oncopeptides AB, Stockholm., Richardson PG; Dana-Farber Cancer Institute, Boston, MA., Mateos MV; Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca.

Publikováno v: Haematologica [Haematologica] 2024 Mar 01; Vol. 109 (3), pp. 895-905. Date of Electronic Publication: 2024 Mar 01.

Phenotypes indicating cytolytic properties of Borrelia-specific interferon-γ secreting cells in chronic Lyme neuroborreliosis

Autor: Ekerfelt, C. ^*, Jarefors, S., Tynngård, N., Hedlund, M., Sander, B., Bergström, S., Forsberg, P., Ernerudh, J.

Publikováno v: In Journal of Neuroimmunology 2003 145(1):115-126

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

Autor: Mateos, M, Szarejko, M, Bila, J, Schjesvold, F, Spicka, I, Maisnar, V, Jurczyszyn, A, Grudeva-Popova, Z, Hajek, R, Usenko, G, Thuresson, M, Norin, S, Jarefors, S, Richardson, P, Pour, L

Publikováno v: HemaSphere; May2023 Supplement S2, Vol. 7, p29-30, 2p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.